Vascular effects of estrogens: rapid actions, novel mechanisms, and potential therapeutic implications

被引:0
作者
Barton, M [1 ]
机构
[1] Univ Zurich, Univ Zurich Hosp, CH-8091 Zurich, Switzerland
[2] Univ Zurich, Cardiovasc Res Lab, Inst Physiol, CH-8091 Zurich, Switzerland
来源
ACTA PHARMACOLOGICA SINICA | 1999年 / 20卷 / 08期
关键词
estrogens; bradykinin; arteries; endothelins; nitric oxide; postmenopause; vasodilation;
D O I
暂无
中图分类号
O6 [化学];
学科分类号
0703 ;
摘要
Although estrogen-dependent effects on the vasculature were first observed more than a century ago, many of the mechanisms by which estrogens interact with the vascular wall have been identified only in the past 15 years. Estrogens bind to vascular estrogen receptors (ER), including the ER alpha, the novel ERP as well as to membrane-bound receptors. Estrogens have direct effects in human coronary and internal mammary arteries by inducing rapid, endothelium-independent relaxation, enhancement of endothelial function and inhibition of vasoconstriction by vasoactive agonists. Furthermore, estrogens contribute to vascular homeostasis through modulation of gene expression, changes in membrane potentials, as well as expression and function of receptors. In addition, estrogens interfere with the activity of vasoactive peptides and vascular enzymes and act as natural antioxidants. Some of these effects have also been observed for phyto-estrogens, which are important dietary components in Asian countries. In the vasculature, the sum of these actions of estrogens results in vasodilatation and inhibition of vascular cell growth. Accordingly, estrogens have been shown to improve vascular function of animals and humans and to inhibit the response to injury after balloon angioplasty and the progression of atherosclerosis. Prospective clinical studies are ongoing to determine whether replacement therapy with estrogen or derivatives provides an alternative to lower cardiovascular mortality in postmenopausal women.
引用
收藏
页码:682 / 690
页数:9
相关论文
共 126 条
[1]   Estrogen replacement therapy and outcome of coronary balloon angioplasty in postmenopausal women [J].
Abu-Halawa, SA ;
Thompson, K ;
Kirkeeide, RL ;
Vaughn, WK ;
Rosales, O ;
Fujisi, K ;
Schroth, G ;
Smalling, R ;
Anderson, HV .
AMERICAN JOURNAL OF CARDIOLOGY, 1998, 82 (04) :409-413
[2]   Medroxyprogesterone acetate antagonizes inhibitory effects of conjugated equine estrogens on coronary artery atherosclerosis [J].
Adams, MR ;
Register, TC ;
Golden, DL ;
Wagner, JD ;
Williams, JK .
ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY, 1997, 17 (01) :217-221
[3]   Soy protein versus soy phytoestrogens in the prevention of diet-induced coronary artery atherosclerosis of male cynomolgus monkeys [J].
Anthony, MS ;
Clarkson, TB ;
Bullock, BC ;
Wagner, JD .
ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY, 1997, 17 (11) :2524-2531
[4]   Ethinylestradiol does not enhance the expression of nitric oxide synthase in bovine endothelial cells but increases the release of bioactive nitric oxide by inhibiting superoxide anion production [J].
Arnal, JF ;
Clamens, S ;
Pechet, C ;
NegreSalvayre, A ;
Allera, C ;
Girolami, JP ;
Salvayre, R ;
Bayard, F .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1996, 93 (09) :4108-4113
[5]   Endothelin receptors are modulated in association with endogenous fluctuations in estrogen [J].
Barber, DA ;
Sieck, GC ;
Fitzpatrick, LA ;
Miller, VM .
AMERICAN JOURNAL OF PHYSIOLOGY-HEART AND CIRCULATORY PHYSIOLOGY, 1996, 271 (05) :H1999-H2006
[6]   Hormone and nonhormone therapy for the maintenance of postmenopausal health: The need for randomized controlled trials of estrogen and raloxifene [J].
Barrett-Connor, E ;
Wenger, NK ;
Grady, D ;
Mosca, L ;
Collins, P ;
Kornitzer, M ;
Cox, DA ;
Moscarelli, E ;
Anderson, PW .
JOURNAL OF WOMENS HEALTH, 1998, 7 (07) :839-847
[7]   ESTROGEN AND CORONARY HEART-DISEASE IN WOMEN [J].
BARRETTCONNOR, E ;
BUSH, TL .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1991, 265 (14) :1861-1867
[8]   17β-estradiol acutely improves endothelium-dependent relaxation to bradykinin in isolated human coronary arteries [J].
Barton, M ;
Cremer, J ;
Mügge, A .
EUROPEAN JOURNAL OF PHARMACOLOGY, 1998, 362 (01) :73-76
[9]   ETA receptor blockade prevents increased tissue endothelin-1, vascular hypertrophy, and endothelial dysfunction in salt-sensitive hypertension [J].
Barton, M ;
d'Uscio, LV ;
Shaw, S ;
Meyer, P ;
Moreau, P ;
Lüscher, TF .
HYPERTENSION, 1998, 31 (01) :499-504
[10]   Estrogen inhibits endothelin production in human endothelial cells: Evidence for NO-independent, estrogen receptor-mediated mechanisms and thrombin-mediated superoxide release [J].
Barton, M ;
Shaw, S ;
Hishikawa, K ;
Joch, H ;
Luscher, TF .
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 1998, 31 (02) :213A-213A